HC Wainwright Estimates NovoCure’s Q2 Earnings (NASDAQ:NVCR)

NovoCure Limited (NASDAQ:NVCR) – Research analysts at HC Wainwright increased their Q2 2026 earnings per share estimates for shares of NovoCure in a note issued to investors on Thursday, April 30th. HC Wainwright analyst E. Bodnar now expects that the medical equipment provider will earn ($0.23) per share for the quarter, up from their previous estimate of ($0.28). HC Wainwright currently has a “Buy” rating and a $49.00 price objective on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for NovoCure’s Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($1.26) EPS, FY2027 earnings at ($1.07) EPS, FY2028 earnings at $0.17 EPS, FY2029 earnings at $2.07 EPS and FY2030 earnings at $4.31 EPS.

A number of other equities research analysts have also recently weighed in on NVCR. Weiss Ratings restated a “sell (e+)” rating on shares of NovoCure in a research note on Tuesday, April 21st. Wedbush restated a “neutral” rating and set a $18.00 price objective on shares of NovoCure in a research note on Thursday, April 16th. Evercore restated an “outperform” rating on shares of NovoCure in a research note on Friday. Finally, Wells Fargo & Company upped their price objective on NovoCure from $13.50 to $17.00 and gave the stock an “equal weight” rating in a research note on Monday. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $27.29.

NovoCure Trading Up 1.9%

Shares of NASDAQ NVCR opened at $16.93 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.90 and a quick ratio of 2.71. The stock has a market capitalization of $1.96 billion, a P/E ratio of -11.07 and a beta of 0.90. NovoCure has a 1-year low of $9.82 and a 1-year high of $20.06. The business has a fifty day moving average price of $12.11 and a 200 day moving average price of $12.44.

NovoCure (NASDAQ:NVCR) last issued its earnings results on Thursday, April 30th. The medical equipment provider reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). The firm had revenue of $174.06 million during the quarter, compared to analysts’ expectations of $167.77 million. NovoCure had a negative return on equity of 50.34% and a negative net margin of 25.66%.NovoCure’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.31) earnings per share.

Insider Activity at NovoCure

In related news, Chairman William F. Doyle sold 71,887 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $12.98, for a total transaction of $933,093.26. Following the transaction, the chairman directly owned 328,397 shares of the company’s stock, valued at $4,262,593.06. This represents a 17.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Christoph Brackmann sold 6,412 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $13.31, for a total value of $85,343.72. Following the transaction, the chief financial officer directly owned 182,842 shares in the company, valued at $2,433,627.02. This represents a 3.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 140,041 shares of company stock worth $1,860,116 over the last ninety days. Corporate insiders own 5.52% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in NVCR. Empowered Funds LLC acquired a new position in NovoCure during the 4th quarter valued at about $33,000. Kestra Advisory Services LLC acquired a new position in NovoCure during the 4th quarter valued at about $49,000. Larson Financial Group LLC increased its position in NovoCure by 662.1% during the 3rd quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock valued at $53,000 after buying an additional 3,562 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in NovoCure by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,442 shares of the medical equipment provider’s stock valued at $70,000 after buying an additional 1,120 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in NovoCure during the 1st quarter valued at about $87,000. 84.61% of the stock is owned by institutional investors and hedge funds.

NovoCure News Summary

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: HC Wainwright raised near‑term EPS forecasts (Q2–Q4 2026) — analyst E. Bodnar trimmed losses for upcoming quarters (Q2 to ($0.23), Q3 to ($0.22), Q4 to ($0.19)), signaling slightly better near‑term profitability expectations; HC Wainwright still maintains a “Buy” rating and a $49 target. MarketBeat NVCR coverage
• Neutral Sentiment: Wells Fargo raised its price target to $17.00 and kept an “Equal Weight” rating — a modest upside tweak that gives near‑term technical/price support but is not a strong bullish endorsement. Benzinga article
• Neutral Sentiment: Media coverage highlights improving relative price strength and a Zacks deep‑dive on NovoCure’s international revenue trends — useful context for growth expectations but not an immediate catalyst. MSN piece Zacks deep dive
• Negative Sentiment: HC Wainwright cut medium‑ and long‑term EPS estimates substantially (FY2026 → ($1.26), FY2027 → ($1.07), FY2028 → $0.17, FY2029 → $2.07, FY2030 → $4.31 from higher prior figures), reflecting weaker longer‑term profitability assumptions and lowering forward earnings visibility despite the Buy rating. MarketBeat NVCR coverage

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.